Advanced search
Publication Cover
Libyan Journal of Medicine Volume 14, 2019 - Issue 1
Submit an article Journal homepage
2,418
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Initial increase in glucose variability during Ramadan fasting in non-insulin-treated patients with diabetes type 2 using continuous glucose monitoring

Nesreen Aldawia Rashid Center for Diabetes and Research, Shiekh Khalifa Medical City Ajman, Ajman, UAE
,
Gassan Darwichea Rashid Center for Diabetes and Research, Shiekh Khalifa Medical City Ajman, Ajman, UAE
,
Salah Abusnanaa Rashid Center for Diabetes and Research, Shiekh Khalifa Medical City Ajman, Ajman, UAE
,
Murtada Elbagira Rashid Center for Diabetes and Research, Shiekh Khalifa Medical City Ajman, Ajman, UAE
&
Targ Elgzyrib Endocrinology department, Skåne University Hospital, Malmo, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2376-3743
ORCID Icon
Article: 1535747 | Received 28 Jul 2018, Accepted 09 Oct 2018, Published online: 22 Oct 2018

References

  • Afandi B, Kaplan W, Al Hassani N, et al. Correlation between pre-ramadan glycemic control and subsequent glucose fluctuation during fasting in adolescents with Type 1 diabetes. J Endocrinol Invest. 2017;40:1–5.
  • Kaplan W, Afandi B. Blood glucose fluctuation during Ramadan fasting in adolescents with type 1 diabetes: findings of continuous glucose monitoring. Diabetes Care. 2015;38:e162–e163.
  • Kaplan W, Afandi B, Al Hassani N, et al. Comparison of continuous glucose monitoring in adolescents with type 1 diabetes: Ramadan versus non-Ramadan. Diabetes Res Clin Pract. 2017;134:178–182.
  • Khalil AB, Beshyah SA, Abu Awad SM, et al. Ramadan fasting in diabetes patients on insulin pump therapy augmented by continuous glucose monitoring: an observational real-life study. Diabetes Technol Ther. 2012;14:813–818.
  • Lessan N, Hannoun Z, Hasan H, et al. Glucose excursions and glycaemic control during Ramadan fasting in diabetic patients: insights from continuous glucose monitoring (CGM). Diabetes Metab. 2015;41:28–36.
  • Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Ther. 2017;19:S16–S26.
  • American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S55–S64.
  • Ibrahim M, Abu Al Magd M, Annabi FA, et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care. 2015;3:e000108.
  • Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65:1132–1140.
  • Anwar A, Azmi KN, Hamidon BB, et al. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia. 2006;61:28–35.
  • Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012;28:1289–1296.
  • Azar ST, Echtay A, Wan Bebakar WM, et al. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial. Diabetes Obes Metab. 2016;18:1025–1033.
  • Glimepiride in Ramadan Study G. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care. 2005;28:421–422.
  • Hassanein M, Echtay A, Hassoun A, et al. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). Int J Clin Pract. 2017;71:e12991.
  • Khattab M, Mahmoud K, Shaltout I. Effect of vildagliptin versus sulfonylurea in muslim patients with type 2 diabetes fasting during Ramadan in Egypt: results from VIRTUE study. Diabetes Ther. 2016;7:551–560.
  • Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319–326.
  • Mbanya JC, Al-Sifri S, Abdel-Rahim A, et al. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. Diabetes Res Clin Pract. 2015;109:226–232.
  • Bashier A, Khalifa AA, Abdelgadir EI, et al. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2-I) during the month of Ramadan in muslim patients with type 2 diabetes. Oman Med J. 2018;33:104–110.
  • Mudher Mikhael E. Effectiveness and safety of newer antidiabetic medications for Ramadan fasting diabetic patients. J Diabetes Res. 2016;2016:6962574.
  • Ahmedani MY, Ahsan S, Haque MSU. Role of Ramadan specific diabetes education (RSDE): A prospective study. Pak J Med Sci. 2017;33:586–593.
  • El Toony LF, Hamad DA, Omar OM. Outcome of focused pre-Ramadan education on metabolic and glycaemic parameters in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2018 Apr 25;12: 761–767.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.